Provided by Tiger Trade Technology Pte. Ltd.

ANTENGENE-B

3.450
0.000
Volume:722.00K
Turnover:2.47M
Market Cap:2.34B
PE:-7.77
High:3.530
Open:3.530
Low:3.330
Close:3.450
52wk High:7.640
52wk Low:2.760
Shares:677.00M
HK Float Shares:677.00M
Volume Ratio:0.86
T/O Rate:0.11%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-0.444
ROE:6.39%
ROA:7.18%
PB:2.19
PE(LYR):-7.77
PS:3.54

Loading ...

Antengene Corp - to Receive About $20 Mln Upfront and Near-Term Consideration

THOMSON REUTERS
·
Jun 22

Antengene Corp - Enters Exclusive License Agreement With K2 Therapeutics for Atg-106

THOMSON REUTERS
·
Jun 22

Antengene-B Announces Appointment of New Co-Company Secretaries

Stock News
·
Jun 10

Antengene Reshuffles Joint Company Secretaries and Secures Three-Year HKEX Compliance Waiver

Bulletin Express
·
Jun 10

Antengene names Ying Liu, Chin Hei Lam as joint company secretaries, replacing Yang Cao, Wai Chiu Wong

Reuters
·
Jun 10

BRIEF-Antengene Says China NMPA Approves IND Application For Phase I Study Of ATG-201

Reuters
·
Jun 10

Antengene Secures China IND Approval for Autoimmune Disease Drug

MT Newswires Live
·
Jun 10

ANTENGENE-B Receives Chinese IND Approval for ATG-201 in Autoimmune Disease Treatment

Stock News
·
Jun 10

Antengene Gains NMPA IND Clearance for ATG-201 CD19×CD3 T-Cell Engager Targeting Autoimmune Diseases

Bulletin Express
·
Jun 10

Antengene - China Nmpa Approves Ind Application for Phase I Study of Atg-201

THOMSON REUTERS
·
Jun 10

Antengene to present first preclinical data on ATG-207 autoimmune drug candidate at EULAR 2026

Reuters
·
Jun 03

Several Insiders Invested In Antengene Flagging Positive News

Simply Wall St.
·
Jun 02

ANTENGENE-B Shares Surge Over 5% Following Clinical Approval for Key Phase III Study of ADC Therapy ATG-022 in Gastric Adenocarcinoma

Stock News
·
May 29

Antengene Secures Chinese Regulatory Nod for Phase 3 Trial

MT Newswires Live
·
May 28

BRIEF-Antengene Receives CDE Endorsement For Phase III Clinch-3 Study Of ATG-22 In China

Reuters
·
May 28

ANTENGENE-B Secures Chinese Nod for Pivotal Phase III Trial of CLDN18.2-Targeting ADC in Gastric Cancers

Stock News
·
May 28

Antengene Secures CDE Green Light for Pivotal Phase III CLINCH-3 Trial of ATG-022 in CLDN18.2-Positive Gastric and GEJ Cancer

Bulletin Express
·
May 28

Antengene wins China IND clearance for Phase III ATG-022 gastric cancer trial

Reuters
·
May 28

Antengene - Receives Cde Endorsement for Phase Iii Clinch-3 Study of Atg-22 in China

THOMSON REUTERS
·
May 28

Antengene Appoints Chief Scientific Officer

MT Newswires Live
·
May 20